Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a leading generics drugmaker. Now with its innovative drug franchise ...

UBS global head of Biotechnology Research Michael Yee is bullish on biopharma stocks for the year ahead, declaring the sector is “ready to take off” after enduring a difficult three-to-four-year ...

One day, probably in the next year or two, a company will claim it has put the first artificial-intelligence-designed antibody in the clinic. But the industry is divided on what “AI-designed” really ...

In 2025, biopharma layoffs showed no signs of slowing, instead rising 16% year over year. Last year was challenging across the board. In a time that was expected to usher in some sort of recovery from ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Uncertainty reigned early this year with the inauguration of President Donald Trump and his threats to impose tariffs and slash prescription drug prices. But as players in the biopharma industry have ...

Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development ...

DKSH Holding AG, the Zurich-based distribution firm, is among bidders vying to acquire Swiss drug distribution company Swixx Biopharma SA, according to people familiar with the matter. Swixx has also ...

It’s all change at Prelude Therapeutics. The precision oncology biotech is waving goodbye to its chief medical officer, pausing work on SMARCA2 degraders and selling a licensing option to Incyte. This ...